PDCD1 and B-cell chronic lymphocytic leukemia: (137) concluded that although PD-L1 mAbs are superior to PD-1 mAbs in inducing anti-CLL T-cell activity, PD-1 mAbs and PD-L1 mAbs monotherapies are largely ineffective in overcoming T-cell tolerance in CLL.